CN101688240A - 通过微rna预测癌症患者的治疗后存活预期 - Google Patents

通过微rna预测癌症患者的治疗后存活预期 Download PDF

Info

Publication number
CN101688240A
CN101688240A CN200880011562A CN200880011562A CN101688240A CN 101688240 A CN101688240 A CN 101688240A CN 200880011562 A CN200880011562 A CN 200880011562A CN 200880011562 A CN200880011562 A CN 200880011562A CN 101688240 A CN101688240 A CN 101688240A
Authority
CN
China
Prior art keywords
hsa
expression level
survival
expection
mir221
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880011562A
Other languages
English (en)
Chinese (zh)
Inventor
陈健尉
俞松良
陈璇宇
张基晟
陈志毅
杨泮池
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Taiwan University
DCB USA LLC
Original Assignee
National Taiwan University
DCB USA LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Taiwan University, DCB USA LLC filed Critical National Taiwan University
Publication of CN101688240A publication Critical patent/CN101688240A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN200880011562A 2007-04-10 2008-04-09 通过微rna预测癌症患者的治疗后存活预期 Pending CN101688240A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91099307P 2007-04-10 2007-04-10
US60/910,993 2007-04-10
PCT/US2008/059767 WO2008124777A1 (en) 2007-04-10 2008-04-09 Predicting post-treatment survival in cancer patients with micrornas

Publications (1)

Publication Number Publication Date
CN101688240A true CN101688240A (zh) 2010-03-31

Family

ID=39831416

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880011562A Pending CN101688240A (zh) 2007-04-10 2008-04-09 通过微rna预测癌症患者的治疗后存活预期

Country Status (13)

Country Link
US (1) US7745134B2 (cg-RX-API-DMAC10.html)
EP (1) EP2134874A4 (cg-RX-API-DMAC10.html)
JP (1) JP2010523156A (cg-RX-API-DMAC10.html)
KR (1) KR20100027102A (cg-RX-API-DMAC10.html)
CN (1) CN101688240A (cg-RX-API-DMAC10.html)
AU (1) AU2008237036A1 (cg-RX-API-DMAC10.html)
CA (1) CA2695868A1 (cg-RX-API-DMAC10.html)
CO (1) CO6231056A2 (cg-RX-API-DMAC10.html)
IL (1) IL201298A0 (cg-RX-API-DMAC10.html)
MX (1) MX2009010899A (cg-RX-API-DMAC10.html)
RU (1) RU2009141359A (cg-RX-API-DMAC10.html)
TW (1) TWI367949B (cg-RX-API-DMAC10.html)
WO (1) WO2008124777A1 (cg-RX-API-DMAC10.html)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108320806A (zh) * 2018-05-09 2018-07-24 中国科学院昆明动物研究所 一种基于多基因表达特征谱的结肠癌个性化预后评估方法
CN108363907A (zh) * 2018-05-09 2018-08-03 中国科学院昆明动物研究所 一种基于多基因表达特征谱的肺腺癌个性化预后评估方法
CN108470111A (zh) * 2018-05-09 2018-08-31 中国科学院昆明动物研究所 一种基于多基因表达特征谱的胃癌个性化预后评估方法
CN108611416A (zh) * 2018-05-09 2018-10-02 中国科学院昆明动物研究所 一种基于多基因表达特征谱的宫颈癌个性化预后评估方法
CN108630317A (zh) * 2018-05-09 2018-10-09 中国科学院昆明动物研究所 一种基于多基因表达特征谱的肝癌个性化预后评估方法
CN108648826A (zh) * 2018-05-09 2018-10-12 中国科学院昆明动物研究所 一种基于多基因表达特征谱的胰腺癌个性化预后评估方法
CN108647493A (zh) * 2018-05-09 2018-10-12 中国科学院昆明动物研究所 一种基于多基因表达特征谱的肾透明细胞癌个性化预后评估方法
CN108733980A (zh) * 2018-05-09 2018-11-02 中国科学院昆明动物研究所 一种基于多基因表达特征谱的胶质母细胞瘤个性化预后评估方法
CN111172285A (zh) * 2020-02-26 2020-05-19 江南大学附属医院 用于胰腺癌早期诊断和/或预后监测的miRNA组及其应用
CN111354421A (zh) * 2018-12-24 2020-06-30 奎克生技光电股份有限公司 健康风险评估方法

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007016548A2 (en) 2005-08-01 2007-02-08 The Ohio State University Research Foundation Micro-rna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer
US8481505B2 (en) 2005-09-12 2013-07-09 The Ohio State University Research Foundation Compositions and methods for the diagnosis and therapy of BCL2-associated cancers
EP2484782B1 (en) 2006-01-05 2015-11-18 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers
WO2007081680A2 (en) 2006-01-05 2007-07-19 The Ohio State University Research Foundation Microrna expression abnormalities in pancreatic endocrine and acinar tumors
AU2007205234B2 (en) 2006-01-05 2012-07-12 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
ES2446362T3 (es) 2006-03-20 2014-03-07 The Ohio State University Research Foundation Huellas de microARN durante megacariocipoyesis humana
ES2425387T3 (es) 2006-07-13 2013-10-15 The Ohio State University Research Foundation Mir-106a para diagnosticar adenocarcinoma de colon de pronóstico de supervivencia pobre
US8071292B2 (en) 2006-09-19 2011-12-06 The Ohio State University Research Foundation Leukemia diagnostic methods
WO2008054828A2 (en) 2006-11-01 2008-05-08 The Ohio State University Research Foundation Microrna expression signature for predicting survival and metastases in hepatocellular carcinoma
JP2010516291A (ja) 2007-01-31 2010-05-20 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション 急性骨髄性白血病（ａｍｌ）の診断、予後及び治療のためのマイクロｒｎａに基づく方法及び組成物
US8465917B2 (en) 2007-06-08 2013-06-18 The Ohio State University Research Foundation Methods for determining heptocellular carcinoma subtype and detecting hepatic cancer stem cells
US8053186B2 (en) 2007-06-15 2011-11-08 The Ohio State University Research Foundation Oncogenic ALL-1 fusion proteins for targeting Drosha-mediated microRNA processing
EP2173911B1 (en) 2007-07-31 2014-06-18 The Ohio State University Research Foundation Methods for reverting methylation by targeting dnmt3a and dnmt3b
EP2653561B1 (en) 2007-08-03 2016-03-02 The Ohio State University Research Foundation Ultraconserved regions encoding ncRNAs
EP3028708A1 (en) 2007-08-22 2016-06-08 The Ohio State University Research Foundation Methods and compositions for inducing deregulation of epha7 and erk phosphorylation in human acute leukemias
WO2009055773A2 (en) 2007-10-26 2009-04-30 The Ohio State University Research Foundation Methods for identifying fragile histidine triad (fhit) interaction and uses thereof
WO2009152300A1 (en) 2008-06-11 2009-12-17 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Use of mir-26 family as a predictive marker of hepatocellular carcinoma and responsiveness to therapy
WO2010054386A2 (en) * 2008-11-10 2010-05-14 Battelle Memorial Institute Methods, compositions, and devices utilizing microrna to determine physiological conditions
US8729041B2 (en) 2008-12-03 2014-05-20 The Johns Hopkins University Compositions and methods for treating hepatic neoplasia
EP2196543A1 (en) * 2008-12-15 2010-06-16 Koninklijke Philips Electronics N.V. Compositions and methods for micro-rna expression profiling of hepatocellular cancer
WO2010094155A1 (en) * 2009-02-23 2010-08-26 Capitalbio Corporation Methods and compositions diagnosing lung cancer, determining prognosis, and improving patient survival
CN101638656B (zh) * 2009-08-28 2011-05-11 南京医科大学 一种与非小细胞肺癌预后相关的血清/血浆miRNA标志物及其应用
EP2504452A4 (en) 2009-11-23 2014-06-11 Univ Ohio State Res Found MATERIALS AND METHODS FOR INFLUENCING GROWTH, MIGRATION AND INVASION OF TUMOR CELLS
MX342967B (es) * 2009-12-20 2016-10-19 Astute Medical Inc Metodos y composiciones para la diagnosis y prognosis de lesion renal y falla renal.
US20110223607A1 (en) * 2010-03-12 2011-09-15 Quest Diagnostics Investments Incorporated Circulating microrna as a marker for hepatocellular carcinoma
WO2012065049A1 (en) 2010-11-12 2012-05-18 The Ohio State University Research Foundation Materials and methods related to microrna-21, mismatch repair, and colorectal cancer
CA2817982C (en) 2010-11-15 2020-06-30 The Regents Of The University Of Michigan Controlled release mucoadhesive systems
JP2014509852A (ja) 2011-03-07 2014-04-24 ジ・オハイオ・ステート・ユニバーシティ マイクロＲＮＡ−１５５（ｍｉＲ−１５５）により誘導される変異誘発活性は炎症および癌を結び付ける
US8404437B2 (en) 2011-03-29 2013-03-26 Taipei Veterans General Hospital MicroRNA as a cancer progression predictor and its use for treating cancer
WO2012151212A1 (en) * 2011-05-01 2012-11-08 University Of Rochester Multifocal hepatocellular carcinoma microrna expression patterns and uses thereof
JPWO2013038737A1 (ja) 2011-09-16 2015-03-23 Ｌｓｉｐファンド運営合同会社 膀胱癌細胞の検出方法、膀胱癌細胞の検出方法に用いるプライマー及び膀胱癌マーカ
CA2852066A1 (en) 2011-10-14 2013-04-18 The Ohio State University Methods and materials related to ovarian cancer
EP2790735A4 (en) 2011-12-13 2015-12-09 Ohio State Innovation Foundation METHODS AND COMPOSITIONS RELATING TO MIR-21 AND MIR-29A, EXOSOME INHIBITION, AND CANCER METASTASIS
US9850541B2 (en) * 2011-12-19 2017-12-26 Valley Health System Methods and kits for detecting subjects at risk of having cancer
JP2015511121A (ja) 2012-01-20 2015-04-16 ジ・オハイオ・ステート・ユニバーシティ 浸潤性および予後に関する乳がんバイオマーカーシグネチャー
US8846316B2 (en) 2012-04-30 2014-09-30 Industrial Technology Research Institute Biomarker for human liver cancer
US10738363B2 (en) 2016-08-31 2020-08-11 National Central University Analyzer and analytical method for predicting prognosis of cancer radiotherapy
DE102018110526A1 (de) 2018-05-02 2019-11-07 Faurecia Autositze Gmbh Verfahren zur Montage eines Linearaktuators für einen Kraftfahrzeugsitz
US11410745B2 (en) * 2018-06-18 2022-08-09 International Business Machines Corporation Determining potential cancer therapeutic targets by joint modeling of survival events
TWI878107B (zh) * 2024-04-30 2025-03-21 朱旆億 乳癌預後存活率預測模型建立方法及系統

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004029287A2 (en) * 2002-09-27 2004-04-08 Oridis Biomed Forschungs- Und Entwicklungs Gmbh Polypeptides and nucleic acids encoding these and their use for the prevention, diagnosis or treatment of liver disorders and epithelial cancer
ATE546528T1 (de) * 2002-11-13 2012-03-15 Univ Jefferson Zusammensetzungen und verfahren zur diagnose und behandlung von krebs
EP1713938A2 (en) * 2004-02-09 2006-10-25 Thomas Jefferson University DIAGNOSIS AND TREATMENT OF CANCERS WITH MicroRNA LOCATED IN OR NEAR CANCER-ASSOCIATED CHROMOSOMAL FEATURES
US20050272067A1 (en) * 2004-03-10 2005-12-08 Macina Roberto A Compositions, splice variants and methods relating to cancer specific genes and proteins
US20060078913A1 (en) * 2004-07-16 2006-04-13 Macina Roberto A Compositions, splice variants and methods relating to cancer specific genes and proteins
US20070065844A1 (en) * 2005-06-08 2007-03-22 Massachusetts Institute Of Technology Solution-based methods for RNA expression profiling

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108470111B (zh) * 2018-05-09 2022-01-18 中国科学院昆明动物研究所 一种基于多基因表达特征谱的胃癌个性化预后评估方法
CN108611416B (zh) * 2018-05-09 2020-12-29 中国科学院昆明动物研究所 一种基于多基因表达特征谱的宫颈癌个性化预后评估方法
CN108470111A (zh) * 2018-05-09 2018-08-31 中国科学院昆明动物研究所 一种基于多基因表达特征谱的胃癌个性化预后评估方法
CN108611416A (zh) * 2018-05-09 2018-10-02 中国科学院昆明动物研究所 一种基于多基因表达特征谱的宫颈癌个性化预后评估方法
CN108630317A (zh) * 2018-05-09 2018-10-09 中国科学院昆明动物研究所 一种基于多基因表达特征谱的肝癌个性化预后评估方法
CN108648826A (zh) * 2018-05-09 2018-10-12 中国科学院昆明动物研究所 一种基于多基因表达特征谱的胰腺癌个性化预后评估方法
CN108647493A (zh) * 2018-05-09 2018-10-12 中国科学院昆明动物研究所 一种基于多基因表达特征谱的肾透明细胞癌个性化预后评估方法
CN108733980A (zh) * 2018-05-09 2018-11-02 中国科学院昆明动物研究所 一种基于多基因表达特征谱的胶质母细胞瘤个性化预后评估方法
CN108363907A (zh) * 2018-05-09 2018-08-03 中国科学院昆明动物研究所 一种基于多基因表达特征谱的肺腺癌个性化预后评估方法
CN108648826B (zh) * 2018-05-09 2022-04-15 中国科学院昆明动物研究所 一种基于多基因表达特征谱的胰腺癌个性化预后评估方法
CN108630317B (zh) * 2018-05-09 2022-04-15 中国科学院昆明动物研究所 一种基于多基因表达特征谱的肝癌个性化预后评估方法
CN108363907B (zh) * 2018-05-09 2022-01-18 中国科学院昆明动物研究所 一种基于多基因表达特征谱的肺腺癌个性化预后评估方法
CN108320806A (zh) * 2018-05-09 2018-07-24 中国科学院昆明动物研究所 一种基于多基因表达特征谱的结肠癌个性化预后评估方法
CN108647493B (zh) * 2018-05-09 2022-01-18 中国科学院昆明动物研究所 一种肾透明细胞癌个性化预后评估方法
CN108733980B (zh) * 2018-05-09 2022-01-18 中国科学院昆明动物研究所 基于多基因表达特征谱胶质母细胞瘤个性化预后评估方法
CN108320806B (zh) * 2018-05-09 2022-04-12 中国科学院昆明动物研究所 一种基于多基因表达特征谱的结肠癌个性化预后评估方法
CN111354421A (zh) * 2018-12-24 2020-06-30 奎克生技光电股份有限公司 健康风险评估方法
CN111172285A (zh) * 2020-02-26 2020-05-19 江南大学附属医院 用于胰腺癌早期诊断和/或预后监测的miRNA组及其应用

Also Published As

Publication number Publication date
EP2134874A1 (en) 2009-12-23
TWI367949B (en) 2012-07-11
JP2010523156A (ja) 2010-07-15
WO2008124777A1 (en) 2008-10-16
AU2008237036A2 (en) 2010-09-09
AU2008237036A1 (en) 2008-10-16
KR20100027102A (ko) 2010-03-10
IL201298A0 (en) 2010-05-31
CA2695868A1 (en) 2008-10-16
TW200912002A (en) 2009-03-16
RU2009141359A (ru) 2011-05-20
US7745134B2 (en) 2010-06-29
MX2009010899A (es) 2010-02-17
US20080254473A1 (en) 2008-10-16
CO6231056A2 (es) 2010-12-20
EP2134874A4 (en) 2010-12-22

Similar Documents

Publication Publication Date Title
WO2008124777A1 (en) Predicting post-treatment survival in cancer patients with micrornas
Li et al. Identification of intrinsic subtype-specific prognostic microRNAs in primary glioblastoma
Li et al. Survival prediction of gastric cancer by a seven-microRNA signature
Davidson et al. MicroRNA-218 is deleted and downregulated in lung squamous cell carcinoma
Childs et al. Low-level expression of microRNAs let-7d and miR-205 are prognostic markers of head and neck squamous cell carcinoma
Hu et al. Serum MicroRNA signatures identified in a genome-wide serum MicroRNA expression profiling predict survival of non–small-cell lung cancer
Gao et al. Genome‐wide small nucleolar RNA expression analysis of lung cancer by next‐generation deep sequencing
Feber et al. MicroRNA prognostic signature for nodal metastases and survival in esophageal adenocarcinoma
Spahn et al. Expression of microRNA‐221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence
Wach et al. MicroRNA profiles of prostate carcinoma detected by multiplatform microRNA screening
Donnem et al. MicroRNA signatures in tumor tissue related to angiogenesis in non-small cell lung cancer
Raponi et al. MicroRNA classifiers for predicting prognosis of squamous cell lung cancer
Scarpati et al. A specific miRNA signature correlates with complete pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer
Yan et al. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis
Lu et al. MicroRNA profiling and prediction of recurrence/relapse-free survival in stage I lung cancer
Gee et al. Downregulated microRNAs in the differential diagnosis of malignant pleural mesothelioma
Yuan et al. Circulating microRNA-125b and microRNA-130a expression profiles predict chemoresistance to R-CHOP in diffuse large B-cell lymphoma patients
US20140162887A1 (en) Methods of using gene expression signatures to select a method of treatment, predict prognosis, survival, and/or predict response to treatment
Shen et al. Applications of microRNAs in the diagnosis and prognosis of lung cancer
JP6704861B2 (ja) 癌処置のための個別化三剤治療を選択するための方法
Bi et al. A microRNA signature predicts survival in early stage small-cell lung cancer treated with surgery and adjuvant chemotherapy
EP3119908A2 (en) Determining cancer aggressiveness, prognosis and responsiveness to treatment
CN104854247A (zh) 卵巢癌的预后及分层方法
JP7043404B2 (ja) 早期乳癌における内分泌処置後の残留リスクの遺伝子シグネチャー
Tarasiuk et al. Biomarkers for early detection of pancreatic cancer–miRNAs as a potential diagnostic and therapeutic tool?

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20100331